Menu
Recruiting NCT06993038

Adenosine vs Diltiazem for Treatment of SVT in the ED

Phase IV Interventional Supraventricular Tachycardia (SVT)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: adenosine, diltiazem.
Who it may be relevant to
Registry conditions: Supraventricular Tachycardia (SVT). Basic parameters: 18 years — 100 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

COMparison of Adenosine Versus Diltiazem FOR Supraventricular Tachycardia in the ED (COMFORT-ED) - Pilot Trial

Overview

This is a small, pilot study with a primary goal of assessing patient perceptions of two medication treatments for supraventricular tachycardia in adult patients treated in the Emergency Department.

Interventions

  • Drug adenosine
    IV adenosine at standard doses for SVT (6 mg, 12 mg)
  • Drug diltiazem
    IV diltiazem at standard doses for SVT (0.25 mg/kg)

Primary outcome measures

  • Feasibility outcome [Time frame: From enrollment to the end of ED encounter (up to 24 hours).]
  • Feasibility outcome [Time frame: From enrollment to the end of ED encounter (up to 24 hours).]
  • Feasibility outcome [Time frame: From enrollment to the end of ED encounter (up to 24 hours).]

Eligibility criteria

Inclusion criteria

  • Adult patients (18 years and older)
  • Diagnosis of acute, stable SVT in the emergency department

Exclusion criteria

  • Receipt of IV AV-nodal blocking agents prior to study enrollment (includes adenosine, non-dihydropyridine calcium channel blockers, beta-antagonists in pre-hospital and/or hospital setting).
  • Reported or confirmed personal history of Wolff-Parkinson-White (WPW) syndrome
  • History of heart failure with reduce ejection fraction (HFrEF) (LVEF</= 40%)
  • Severe bronchoconstrictive lung disease
  • Prior hypersensitivity to study medication
  • Previously enrolled in pilot study
  • Pregnant
  • Incarcerated

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Single group
Masking
Single blind
Primary purpose
Treatment

Study locations

United States · 1 center
  • University of Iowa Health Care — Iowa City

Identifiers

NCT: NCT06993038 · 202412202

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗